Table 1. The baseline characteristics of included trials.
| Included references | Sample Capcity* | Follow-up (mo) | Sex** | Age(yr) * | Weight(Kg) or BMI(Kg/m2) * | Wrap length (cm) * | PPI use (%)* | Duration of symptoms* |
|---|---|---|---|---|---|---|---|---|
| Laws 1997[19] | 23/16 | Mean 27.2 | 19/20 | 45.5 / 55.5 | No detail | Average 2.2 [1.6–3] / - | No detail | No detail |
| Chrysos 2003[12] | 14/19 | 12 | 18/15 | 61.7±8.7 / 59.2±11.5 | No detail | 3–4 / 3–4 | No detail | No detail |
| Guérin 2007[20] | 77/63 | 36 | 86/54 | No detail | Median BMI 27/26.6 | 3 / - | No detail | No detail |
| Booth 2008[21] | 64/63 | 12 | 84/43 | 45.3[21–86]/44.2[19–69] | Mean Weight 81.6/80.2 | 2 / - | 92% / 90% | 94.5 (7–516) / 95.6 (6–248) mo |
| Fibbe 2001[22] | 100/100 | 24 | 121/79 | 56[20–80] | Mean BMI 26.4[18.9–40.4] | 2 / - | Average 24 (0.2–180) mo | Median 7 (0.2–50) yr |
| Zornig 2002[23] | ||||||||
| Strate 2008[24] | ||||||||
| Shaw 2010[25] | 50/50 | 60 | 60/40 | 45.2[28–72]/45.6[25–67] | Mean BMI 29.3±5.2/29.2±5.2 | 1 / 2 | No detail | 2.36±0.5 / 2.58±0.6 |
| Mucio 2012[15] | 133/131 | 180 | No detail | No detail | No detail | 2.54 (1 inch) / - | No detail | No detail |
| Koch 2013[16] | 62/63 | 12 | 78/47 | 50.32[20–76]/51.87[25–81] | Mean BMI 28.18[19.47–41.80]/27.32[19.66–3.86] | - / - | No detail | No detail |
| Qin 2013[17] | 215/168 | 12 | 194/189 | 56.3[34–82] | No detail | - / - | No detail | No detail |
| Mickevicius 2008[6] | 76/77 | 60 | 74/79 | 49.2±14.4 / 54.8±12.6 | Mean BMI 27.7±4.6/29.3±3.2 | 1.5 vs. 3 / 1.5 vs. 3 | No detail | 7.2±7.7 / 7.1±7.6 yr |
| Mickevicius 2013[7] |
LNF: Laparoscopic Nissen fundoplication; LTF: Laparoscopic Toupet fundoplication; Mo: Month; yr: year; BMI: Body mass index; PPI: Proton pump inhibitors.
*Data in these columns are showed as data in LNF group/data in LTF group
**Data are showed as number of males/number of female